Related Experiment Video
Updated: Nov 1, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons
Rachel Eikelboom1, Takhliq Amir2, Saurabh Gupta3
1Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba.
Insights
Optimizing medical therapy after coronary artery bypass grafting (CABG) can reduce cardiovascular events. Recent advances in lipid, diabetes, antithrombotic, and anti-inflammatory treatments improve outcomes for post-CABG patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Interventional Cardiology
Background:
- Patients undergoing coronary artery bypass grafting (CABG) face persistent risks of cardiovascular events and mortality.
- Optimizing medical therapy post-CABG presents a critical opportunity for cardiac surgeons to mitigate these risks.
Purpose of the Study:
- To review the principles of optimal medical therapy (OMT) following CABG.
- To summarize recent therapeutic advancements relevant to post-CABG patient care.
Main Methods:
- Literature review of recent developments in cardiovascular pharmacotherapy.
- Focus on practical applications of OMT for cardiac surgeons.
Main Results:
- Novel lipid-lowering agents (PCSK-9 inhibitors, icosapent ethyl) address specific lipid profiles.
- Advanced diabetes management (GLP-1 receptor agonists, SGLT-2 inhibitors) is recommended for all post-CABG patients with type 2 diabetes.
- Intensified antithrombotic therapy (DAPT, DPI) and colchicine show promise in reducing major adverse cardiovascular events (MACE) and mortality in high-risk individuals.
Conclusions:
- Implementing updated OMT strategies is crucial for improving prognosis in post-CABG patients.
- Cardiac surgeons should integrate recent pharmacological advancements into their clinical practice.
- Personalized OMT based on patient-specific risk factors and comorbidities is essential.
Purpose Of Review:
After coronary artery bypass grafting (CABG), patients remain at increased risk of cardiovascular events and death. Cardiac surgeons have the opportunity to reduce this risk by optimizing post-CABG patients' medical therapy.
Recent Findings:
Recent developments in lipid-lowering, diabetes management, antithrombotic therapy, and anti-inflammatory therapy can significantly improve prognosis in patients with chronic coronary artery disease. PCSK-9 inhibitors should be used in patients with elevated LDL cholesterol despite maximally tolerated statin therapy. Icosapent ethyl should be considered in patients with elevated triglycerides despite maximally tolerated statin therapy. Long-acting GLP-1 receptor agonists or SLGT-2 inhibitors should be used in all post-CABG patients with type 2 diabetes. Intensified antithrombotic therapy with DAPT or DPI reduces MACE (and DPI reduces mortality) in patients with high atherosclerotic burden. Colchicine has not yet been incorporated into guidelines on OMT for stable CAD but it is reasonable to consider using it in high-risk patients.
Summary:
We review the foundations of optimal medical therapy after CABG, and summarize recent advances with a focus on practical application for the busy cardiac surgeon.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
12:00Evaluation of a Novel Laser-assisted Coronary Anastomotic Connector - the Trinity Clip - in a Porcine Off-pump Bypass Model
Published on: November 24, 2014
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management